PARIS, June 27, 2011 /PRNewswire/ —
Sanofi (EURONEXT: SAN and NYSE:
SNY) announced today, at the 71st Scientific
American Diabetes Association Sessions 2011, the results of three
studies showing that people with diabetes using Sanofi insulins
Lantus® and/or Apidra® with the
insulin delivery device SoloSTAR® experienced
greater treatment satisfaction, better quality of life and lower
fear of hypoglycemia vs those using a premixed insulin product.
The goal of the first study[1], involving
586 patients with uncontrolled type 2 diabetes on oral agents, was
to evaluate any changes in physical and psychological well-being,
diabetes-related symptoms, and patient satisfaction with
diabetes-related care and treatment over the study period and from
baseline to endpoint.
It showed that, compared with those on twice-daily premixed
70/30 insulin aspart (premix), patients on the combination of
Lantus®– and Apidra®-based regimens
experienced better quality of life as measured by the Diabetes
Quality of Life (DQoL) questionnaire, which evaluates personal
perception of improvements as a result of treatment:
- DQoL improved significantly for all groups at all wks; average
improvement was greater for basal Lantus® (insulin glargine) +
1 prandial Apidra® (insulin glulisine) dose (GLARG+1) and
stepwise addition of prandial glulisine (GLARG+0-3) vs premix
(P≤0.0002) - Compared to the glargine group, patients on premix also showed
significantly greater hypoglycemic fear from week 12 to study end
(P<0.05).
The goal of the second study[2], conducted
with 220 type 1 and type 2 patients from 32 sites in Canada, was to
evaluate the change in diabetes t
‘/>”/>
SOURCE